- Home
- FBIOP vs MGIC Comparison
FBIOP vs MGIC Comparison
Compare FBIOP & MGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIOP
- MGIC
- Stock Information
- Founded
- FBIOP N/A
- MGIC 1983
- Country
- FBIOP United States
- MGIC Israel
- Employees
- FBIOP 186
- MGIC N/A
- Industry
- FBIOP Biotechnology: Pharmaceutical Preparations
- MGIC Computer Software: Prepackaged Software
- Sector
- FBIOP Health Care
- MGIC Technology
- Exchange
- FBIOP Nasdaq
- MGIC Nasdaq
- Market Cap
- FBIOP N/A
- MGIC N/A
- IPO Year
- FBIOP N/A
- MGIC 1991
- Fundamental
- Price
- FBIOP $6.98
- MGIC $12.60
- Analyst Decision
- FBIOP
- MGIC Buy
- Analyst Count
- FBIOP 0
- MGIC 1
- Target Price
- FBIOP N/A
- MGIC $15.00
- AVG Volume (30 Days)
- FBIOP N/A
- MGIC 43.3K
- Earning Date
- FBIOP N/A
- MGIC 03-12-2025
- Dividend Yield
- FBIOP N/A
- MGIC 1.62%
- EPS Growth
- FBIOP N/A
- MGIC N/A
- EPS
- FBIOP N/A
- MGIC 0.70
- Revenue
- FBIOP N/A
- MGIC $535,482,999.00
- Revenue This Year
- FBIOP N/A
- MGIC $4.29
- Revenue Next Year
- FBIOP N/A
- MGIC $3.39
- P/E Ratio
- FBIOP N/A
- MGIC $18.02
- Revenue Growth
- FBIOP N/A
- MGIC N/A
- 52 Week Low
- FBIOP N/A
- MGIC $9.51
- 52 Week High
- FBIOP N/A
- MGIC $13.40
- Technical
- Relative Strength Index (RSI)
- FBIOP 56.58
- MGIC 59.21
- Support Level
- FBIOP $6.75
- MGIC $12.00
- Resistance Level
- FBIOP $6.97
- MGIC $12.82
- Average True Range (ATR)
- FBIOP 0.38
- MGIC 0.29
- MACD
- FBIOP -0.02
- MGIC 0.06
- Stochastic Oscillator
- FBIOP 70.37
- MGIC 84.93
About FBIOP Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.